Product Description
a new generation of NEUGENE(R) antisense drug for treating coronary vascular disease. (Sourced from: https://investorrelations.sarepta.com/news-releases/news-release-details/avi-biopharma-initiates-neugene-antisense-clinical-program)
Mechanisms of Action: C-MYC mRNA Blocker
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sarepta
Company Location: Eastern America
Company CEO: Douglas S. Ingram
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Coronary Artery Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00451256 |
AVI-5126-25 | P2 |
Terminated |
Coronary Artery Disease |
2007-11-01 |
2019-08-10 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|